Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab

Am J Hematol. 2020 Apr;95(4):E76-E77. doi: 10.1002/ajh.25715. Epub 2020 Jan 14.

Authors

Senthil Sukumar¹, James N George², Spero R Cataland¹

Affiliations

¹ Division of Hematology, Department of Medicine, The Ohio State University College of Medicine, Columbus, Ohio.
² Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

ADAMTS13 Protein / deficiency
Decision Making, Shared*
Female
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / pharmacology
Immunosuppressive Agents / therapeutic use*
Infusions, Intravenous
Injections, Subcutaneous
Middle Aged
Patient Preference
Patient-Centered Care
Platelet Count
Purpura, Thrombotic Thrombocytopenic / drug therapy*
Purpura, Thrombotic Thrombocytopenic / enzymology
Recurrence
Remission Induction
Rituximab / therapeutic use
Self Administration
Single-Domain Antibodies / administration & dosage
Single-Domain Antibodies / pharmacology
Single-Domain Antibodies / therapeutic use*
Treatment Refusal
von Willebrand Factor / antagonists & inhibitors

Substances

Immunosuppressive Agents
Single-Domain Antibodies
von Willebrand Factor
caplacizumab
Rituximab
ADAMTS13 Protein
ADAMTS13 protein, human